| Assessment Status | Rapid Review Complete |
| HTA ID | 24048 |
| Drug | Cemiplimab |
| Brand | Libtayo® |
| Indication | Cemiplimab (Libtayo®) is indicated as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 02/12/2024 |
| Rapid review completed | 17/01/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cemiplimab for this indication compared with the current standard of care. |
